AMG National Trust Bank Reduces Holdings in Stryker Co. (NYSE:SYK)

AMG National Trust Bank lessened its stake in Stryker Co. (NYSE:SYK - Free Report) by 7.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,548 shares of the medical technology company's stock after selling 1,306 shares during the quarter. AMG National Trust Bank's holdings in Stryker were worth $5,605,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker during the fourth quarter worth $25,000. Dunhill Financial LLC lifted its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after acquiring an additional 37 shares during the period. Centricity Wealth Management LLC bought a new stake in Stryker during the fourth quarter worth $30,000. BankPlus Trust Department bought a new stake in Stryker during the fourth quarter worth $33,000. Finally, Darwin Wealth Management LLC bought a new stake in Stryker during the third quarter worth $36,000. Institutional investors own 77.09% of the company's stock.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Remove Ads

Stryker Price Performance

NYSE SYK traded down $3.03 during trading on Friday, reaching $379.28. The company's stock had a trading volume of 1,961,830 shares, compared to its average volume of 1,209,637. The stock has a market capitalization of $144.73 billion, a PE ratio of 48.88, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a fifty day moving average of $382.45 and a 200 day moving average of $372.99. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company posted $3.46 EPS. Analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SYK. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Morgan Stanley upgraded Stryker from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Wells Fargo & Company boosted their target price on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Truist Financial boosted their target price on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research note on Thursday, January 30th. Finally, Royal Bank of Canada boosted their target price on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.